- / Jun 05, 2024 / Business Wire / UnitedHealth Group (NYSE: UNH) provided updates on its 2024 annual shareholder meeting and actions by its Board of Directors.
Shareholders elected all those nominated to the Board: Charles Baker, Timothy Flynn, Paul Garcia, Kristen Gil, Stephen Hemsley, Michele Hooper, F. William McNabb III, Valerie Montgomery Rice, M.D., John Noseworthy, M.D., and Andrew Witty.
UnitedHealth Group directors stand for election annually.
Shareholders also:
At its regular quarterly meeting, the Board authorized payment of a cash dividend of $2.10 per share, to be paid June 25, 2024, to common stock shareholders of record as of the close of business June 17, 2024.
About UnitedHealth Group
UnitedHealth Group (NYSE: UNH) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at www.unitedhealthgroup.com and follow UnitedHealth Group on LinkedIn.
Last Trade: | US$303.90 |
Daily Change: | 3.47 1.16 |
Daily Volume: | 9,479,864 |
Market Cap: | US$275.230B |
July 31, 2025 May 13, 2025 January 16, 2025 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load